Last reviewed · How we verify

NCT05137704

A Study on the Use of Healthcare Resources and Costs of Attention Deficit Hyperactivity Disorder (ADHD) in Adults in England

Completed Last updated 12 July 2022
What this trial tests

trial testing No intervention in Attention Deficit Hyperactivity Disorder (ADHD) in 2,236 participants. Completed in 31 March 2022.

Timeline
1 December 2021
Primary endpoint
31 March 2022
31 March 2022

Quick facts

Lead sponsorTakeda
StatusCompleted
Study typeOBSERVATIONAL
Enrollment2,236
Start date1 December 2021
Primary completion31 March 2022
Estimated completion31 March 2022
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Takeda — full company profile →

Who can join

18 and older, any sex, with Attention Deficit Hyperactivity Disorder (ADHD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of the study is to learn about the demographic and clinical characteristics, healthcare resources utilization (HCRU) and costs associated with before and after ADHD diagnosis in England. No study medicines will be provided to participants in this study. The record available in Clinical Practice Research Datalink (CPRD) database and Hospital Episode Statistics (HES) database for ADHD participants will be assessed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Attention Deficit Hyperactivity Disorder (ADHD)

Currently open trials in the same condition.

Other Takeda trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05137704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing